News

Just a summary of all the news articles that we could source from different places. A good way to make an investment decision is also to look at how actively the company is engaging with news sources to keep them in the news. In this day and age its critical to have a media presence.

Please consider a small donation if you think this website provides you with relevant information  

   
Date Title Source
2024-02-25 8:39:56 am Protagonist Therapeutics: Why I Remain On Sidelines Despite Obvious Promise SeekingAlpha
2024-02-21 2:0:0 pm New England Journal of Medicine Publishes Results of Positive Randomized Phase 2 REVIVE Trial of Rusfertide in Treatment of Polycythemia Vera ACCESSWIRE
2024-02-20 1:5:0 pm Protagonist Therapeutics Reports Granting of Inducement Awards ACCESSWIRE
2024-02-15 12:13:53 am Steven Cohen Adjusts Position in Protagonist Therapeutics Inc GuruFocus.com
2024-02-07 2:0:0 pm New England Journal of Medicine Publishes Efficacy and Safety Data of Targeted Oral Peptide JNJ-2113 in a Phase 2b Moderate-To-Severe Plaque Psoriasis Study ACCESSWIRE
2024-02-02 10:3:0 am Protagonist (PTGX) Up 14% on Licensing Deal With Takeda Zacks
2024-02-01 3:35:0 am Takeda pays $300M to license Protagonist drug for blood disorder BioPharma Dive
2024-01-31 1:5:0 pm Takeda and Protagonist Therapeutics, Inc. Enter into Worldwide License and Collaboration Agreement for Rusfertide, a Late-Stage Rare Hematology Asset ACCESSWIRE
2024-01-29 4:30:0 am Protagonist Therapeutics to Participate in Fireside Chat at Guggenheim Healthcare Talks 2024 ACCESSWIRE
   

Please consider a small donation if you think this website provides you with relevant information